These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 16637527)

  • 1. Urban myths and the ACT: what is not true and what really matters when it comes to monitoring anticoagulation.
    Searles B
    J Extra Corpor Technol; 2006 Mar; 38(1):56-8. PubMed ID: 16637527
    [No Abstract]   [Full Text] [Related]  

  • 2. Effects of aprotinin on anticoagulant monitoring: implications in cardiovascular surgery.
    Najman DM; Walenga JM; Fareed J; Pifarré R
    Ann Thorac Surg; 1993 Mar; 55(3):662-6. PubMed ID: 7680854
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effects of aprotinin on heparinized whole blood activated clotting time and whole blood prothrombin time].
    Wen Z; Zhu F; He X; Xiong S; He S
    Hunan Yi Ke Da Xue Xue Bao; 1997; 22(4):304-6. PubMed ID: 9868081
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aprotinin and heparin monitoring during cardiopulmonary bypass.
    Hunt BJ; Segal H; Yacoub M
    Circulation; 1992 Nov; 86(5 Suppl):II410-2. PubMed ID: 1385011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extrinsic pathway--associated activated clotting time for anticoagulation monitoring during cardiopulmonary bypass.
    Gu YJ; Huyzen RJ; van Oeveren W
    Anesth Analg; 1996 Aug; 83(2):433. PubMed ID: 8694335
    [No Abstract]   [Full Text] [Related]  

  • 6. Monitoring of heparin-induced anticoagulation with kaolin-activated clotting time in cardiac surgical patients treated with aprotinin.
    Wang JS; Lin CY; Hung WT; Karp RB
    Anesthesiology; 1992 Dec; 77(6):1080-4. PubMed ID: 1281624
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of heparin, haemodilution and aprotinin on kaolin-based activated clotting time: in vitro comparison of two different point of care devices.
    Dalbert S; Ganter MT; Furrer L; Klaghofer R; Zollinger A; Hofer CK
    Acta Anaesthesiol Scand; 2006 Apr; 50(4):461-8. PubMed ID: 16548858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of MDCO-2010, a serine protease inhibitor, on activated clotting time in blood obtained from volunteers and cardiac surgical patients.
    Kim H; Szlam F; Tanaka KA; van de Locht A; Ogawa S; Levy JH
    Anesth Analg; 2012 Aug; 115(2):244-52. PubMed ID: 22584552
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased anticoagulation during cardiopulmonary bypass by aprotinin.
    de Smet AA; Joen MC; van Oeveren W; Roozendaal KJ; Harder MP; Eijsman L; Wildevuur CR
    J Thorac Cardiovasc Surg; 1990 Oct; 100(4):520-7. PubMed ID: 1699088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The in vitro effects of aprotinin on twelve different ACT tests.
    Jones K; Nasrallah F; Darling E; Clay N; Searles B
    J Extra Corpor Technol; 2004 Mar; 36(1):51-7. PubMed ID: 15095841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anticoagulation policy during use of aprotinin in cardiopulmonary bypass.
    van Oeveren W; van Oeveren B; Wildevuur CR
    J Thorac Cardiovasc Surg; 1992 Jul; 104(1):210-1. PubMed ID: 1377314
    [No Abstract]   [Full Text] [Related]  

  • 12. The effect of temperature and aprotinin during cardiopulmonary bypass on three different methods of activated clotting time measurement.
    Machin D; Devine P
    J Extra Corpor Technol; 2005 Sep; 37(3):265-71. PubMed ID: 16350378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heparin resistance after aprotinin.
    Hunt BJ; Murkin JM
    Lancet; 1993 Jan; 341(8837):126. PubMed ID: 7678119
    [No Abstract]   [Full Text] [Related]  

  • 14. In vitro effects of aprotinin on activated clotting time measured with different activators.
    Wang JS; Lin CY; Hung WT; Thisted RA; Karp RB
    J Thorac Cardiovasc Surg; 1992 Oct; 104(4):1135-40. PubMed ID: 1383640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Guidelines for monitoring heparin by the activated clotting time when aprotinin is used during cardiopulmonary bypass.
    Hunt BJ; Segal HC; Yacoub M
    J Thorac Cardiovasc Surg; 1992 Jul; 104(1):211-2. PubMed ID: 1377315
    [No Abstract]   [Full Text] [Related]  

  • 16. Monitoring of anticoagulation in aprotinin-treated patients during heart operation.
    Tabuchi N; Njo TL; Tigchelaar I; Huyzen RJ; Boonstra PW; van Oeveren W
    Ann Thorac Surg; 1994 Sep; 58(3):774-7. PubMed ID: 7524456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel thrombelastograph tissue factor/kaolin assay of activated clotting times for monitoring heparin anticoagulation during cardiopulmonary bypass.
    Chavez JJ; Foley DE; Snider CC; Howell JC; Cohen E; Muenchen RA; Carroll RC
    Anesth Analg; 2004 Nov; 99(5):1290-1294. PubMed ID: 15502019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the TAS coagulation analyzer for monitoring heparin effect in cardiac surgical patients.
    Gibbs NM; Weightman WM; Thackray NM; Michalopoulos N
    J Cardiothorac Vasc Anesth; 1998 Oct; 12(5):536-41. PubMed ID: 9801974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monitoring activated clotting time for combined heparin and aprotinin application: in vivo evaluation of a new aprotinin-insensitive test using Sonoclot.
    Ganter MT; Monn A; Tavakoli R; Genoni M; Klaghofer R; Furrer L; Honegger H; Hofer CK
    Eur J Cardiothorac Surg; 2006 Aug; 30(2):278-84. PubMed ID: 16828293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heparin sensitivity test for patients requiring cardiopulmonary bypass.
    DeBois WJ; Liu J; Elmer B; Ebrahimi H; Voevidko L; Lee LY; Krieger KH; Isom WW; Girardi LN
    J Extra Corpor Technol; 2006 Dec; 38(4):307-9. PubMed ID: 17312901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.